This manual presents optimal Transfusion Medicine practice guidelines for all levels of physicians responsible for Transfusion Medicine services in BC.
| 1st Edition 2007 |
|
| Table of Contents |
|
|
The Table of Contents provides a quick reference to the manual contents. |
|
| Glossary of Terms and Abbreviations | |
|
The Glossary of Terms and Abbreviations provides a definition of the terms and abbreviations used in the manual |
|
| Introduction |
|
|
Introduction to the manual and overview of the intended audience and applicable standards. An overview of the role and responsibilities of the TM Medical Director (or designate) is provided at the end of the module. This section includes the title page and copyright information if the manual is printed from the pdf modules. |
|
| Section 1.0 Medical Roles and Responsibilities |
|
|
Section 1.0 includes policies applicable to Transfusion Medicine Medical Director (TM-MD) medical roles and responsibilities.
|
|
| Section 2.0 Quality System Management |
|
|
Section 2.0 includes policies applicable to the TM-MD and Transfusion Medicine Service (TMS) staff as related to the management of the TMS quality system.
|
|
| Section 3.0 Informed Consent and Refusal of Consent |
|
|
Section 3.0 includes policies applicable to the TM-MD, Transfusion Medicine Service (TMS) staff, Treating Physician, and Treating Nurse as related to the informed consent, and refusal of consent, process.
|
|
| Section 4.0 Daily Operations |
Revised July 2010 |
|
Section 4.0 includes policies applicable to the TM-MD and the Transfusion Medicine Service (TMS) staff as related to the processes and procedures that define regular, daily operations. This section was reviewed and revised in January 2009 to reflect changes in practice related to the Weakened Expression of the D-Antigen examination. The section was further revised in July 2010 as Transfusion Reaction was moved to a new section of the manual.
|
|
| Section 5.0 Appropriate Use of Blood Components for Adults |
Revised July 2014 |
|
Section 5.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to the appropriate use of blood components for adults.
|
|
|
Revised Dec 2019 |
|
| Section 6.0 Special Product Selection |
Revised May 2013 |
|
Section 6.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to the selection of special blood components. |
|
|
Revised Dec 2019 |
|
|
6.2 Irradiation of Blood Components Note: this section is under review to align with the most recent NAC Recommendations endorsed by TMAG |
Revised Mar 2015 |
|
6.3 Indications for Anti-CMV Negative Red Cells and Platelets Note: this section is under review to align with the most recent NAC Recommendations endorsed by TMAG |
|
|
Revised Aug 2015 |
|
| Section 7.0 Appropriate Use of Other Blood Products |
Revised Jan 2009 |
|
Section 7.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to the appropriate use of blood products, predominantly Albumin and IVIG. This section was reviewed and revised in 2009 to include the 2007 Guidelines for Albumin Use in Adults in BC, and changes made to the IVIG Program in BC.
|
|
|
Revised Aug 2015 |
|
|
7.1.1 Indications for the Use of Albumin |
|
|
7.1.2 Indications for the Use of IVIG |
|
|
7.1.3 Indications for the Use of Other Plasma Fractionated Products |
|
|
7.2 Appropriate Use of Recombinant Products – Recombinant Factors VIIa, VIII and IX, Erythropoietin |
|
| Section 8.0 Appropriate Use of Blood Products in Neonates or Pediatric Patients |
Revised Oct 2013 |
|
Section 8.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to the appropriate use of blood products in neonates or pediatric patients. This section was reviewed and revised in 2013 and added a clinical recommendations section for the appropriate use of blood components in neonates and infants less than 4 months of age.
|
|
|
Revised Jun 2015 |
|
|
Revised Jun 2015 |
|
|
8.6 Transfusion Management of Autoimmune Hemolytic Anemias in Pediatric Patient (See Section 9.3: Transfusion Management of Autoimmune Hemolytic Anemia) |
|
| Section 9.0 Special Transfusion Scenarios |
|
|
Section 9.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to special transfusion scenarios.
|
|
|
9.1 Support of a Patient with Signed Refusal of Consent for Transfusion |
|
|
9.2.1 Switching ABO group in Massive Transfusion or During Inventory Shortage |
|
|
9.2.2 Switching from D-negative to D-positive in Massive Transfusion |
|
|
9.2.3 Massive Transfusion in Recipient with Alloantibodies |
|
|
9.4 Transfusion Support of Minor Incompatible Solid Organ Transplant Recipients |
|
|
9.5 Transfusion Support of Allogeneic Stem Cell and Bone Marrow Transplant Recipients |
|
|
Revised Oct 2023 |
|
| Section 10.0 Disaster Plans |
|
|
Section 10.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to the development and implementation of disaster plans that may be specific to the TMS, or broaden out to include the Health Authority.
|
|
| Section 11.0 Transfusion Reactions |
Revised Apr 2022 |
| Section 11.0 includes policies applicable to the TM-MD and to the Transfusion Medicine Service (TMS) staff as related to the identification, investigation and management of transfusion reactions. | |
| For further guidance on transfusion reaction definitions, severity ratings and outcome classifications refer to the PHAC TTISS User’s Manual V3.0 | |
| Section 12.0 Home Transfusion of Blood Components and Blood Products |
Revised May 2020 |
|
Section 12.0 is a framework describing the considerations that are required to support Clinical and Laboratory Operations when a Home Transfusion is requested. It is meant to facilitate discussion, interventional planning and ultimately the decision to provide safe transfusion outside of an acute care setting. |
|
